Cantor Fitzgerald Reiterates “Overweight” Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They currently have a $170.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 34.77% from the company’s previous close.

ASND has been the topic of several other reports. UBS Group began coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Wedbush reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Oppenheimer lowered their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $191.57.

Ascendis Pharma A/S Stock Up 5.5 %

NASDAQ:ASND opened at $126.14 on Tuesday. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The firm has a market capitalization of $7.66 billion, a P/E ratio of -15.61 and a beta of 0.64. The stock’s fifty day simple moving average is $131.98 and its 200-day simple moving average is $132.22.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts expect that Ascendis Pharma A/S will post -7.12 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in the stock. Groupama Asset Managment bought a new stake in Ascendis Pharma A/S during the third quarter worth $60,000. Janus Henderson Group PLC lifted its stake in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. bought a new stake in Ascendis Pharma A/S during the third quarter worth $19,908,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.